Ablative RT after LOFU treatment would increase the release of tumor derived peptide-HSP complexes for cross-presentation by antigen presenting cells, thereby, increasing the immunogenicity of tumor cells and tumor growth retardation. The gene discussed is HSP90B2P; the disease is neoplasm.